Basanta Sharma Paudel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Basanta Sharma Paudel has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Sangam Shah
Institute of Medicine, Tribhuvan University, Maharajgunj, Nepal
3 shared publications - Madhur Bhattarai
Centinela Hospital Medical Center, Los Angeles, California
2 shared publications - Ranjit Sah
Boston Medical Center Health System, Boston, USA
2 shared publications - Aadhar Oli
Department of Internal Medicine, Rolpa District Hospital, Rolpa, Nepal
1 shared publication Amit Bhandari
Department of Medicine, St. John’s Hospital, Springfield, IL
1 shared publication- Amit Khanal
Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46671
Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46671
Open AccessGastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.
- Open Access
- 3 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (1) , e41150
Evaluation of anemia among pregnant women in a hilly district of western Nepal: A hospital based cross-sectional study
Iron deficiency anemia remains a significant public health concern, particularly among pregnant women and children. The prevalence of anemia is higher in lower middle income countries including Nepal. Despite government efforts, progress in reducing anemia in the last 15 years has been slow, especially in remote hilly regions. While investing in anemia control can yield substantial economic returns, there have not been adequate studies to cover diverse geographical areas of Nepal. This study aims to determine the prevalence of anemia in a hilly district of western Nepal. A retrospective cross-sectional study was conducted among the 350 pregnant women visiting for ante natal checkup in Burtibang primary hospital from July 15, 2022 to Jan 15, 2023. The factors associated with the prevalence of anemia was calculated by using multivariate logistics regression analysis at P < .05 and ANOVA test was done to calculate the differences in hemoglobin level across the different characteristics of the pregnant women. More than 2 out of 5 pregnant women (43.1%) had anemia with 57.6% having mild anemia and 42.4% of the women having moderate to severe level of anemia. The mean Hb level of the pregnant women was 10.8 (±1.0) g/dL. Women on second (adjusted odds ratio [aOR]: 0.06; 95% CI: 0.03–0.11) and third trimester of their pregnancy (aOR: 0.06; 95% CI: 0.02–0.16) had lower odds of having anemia. A moderate level of correlation of Hb level with the gestational age (R = 0.574, P value: <.001) was seen in the study. The prevalence of anemia is a serious public health problem among the women visiting ante natal checkup in Burtibang hospital. Later trimester of the pregnancy had higher risks of having anemia in comparison to the first and the gestational age of the women was a significant predictor of Hb level among the population.
- 3 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (1) , e41150
Open AccessEvaluation of anemia among pregnant women in a hilly district of western Nepal: A hospital based cross-sectional study
Iron deficiency anemia remains a significant public health concern, particularly among pregnant women and children. The prevalence of anemia is higher in lower middle income countries including Nepal. Despite government efforts, progress in reducing anemia in the last 15 years has been slow, especially in remote hilly regions. While investing in anemia control can yield substantial economic returns, there have not been adequate studies to cover diverse geographical areas of Nepal. This study aims to determine the prevalence of anemia in a hilly district of western Nepal. A retrospective cross-sectional study was conducted among the 350 pregnant women visiting for ante natal checkup in Burtibang primary hospital from July 15, 2022 to Jan 15, 2023. The factors associated with the prevalence of anemia was calculated by using multivariate logistics regression analysis at P < .05 and ANOVA test was done to calculate the differences in hemoglobin level across the different characteristics of the pregnant women. More than 2 out of 5 pregnant women (43.1%) had anemia with 57.6% having mild anemia and 42.4% of the women having moderate to severe level of anemia. The mean Hb level of the pregnant women was 10.8 (±1.0) g/dL. Women on second (adjusted odds ratio [aOR]: 0.06; 95% CI: 0.03–0.11) and third trimester of their pregnancy (aOR: 0.06; 95% CI: 0.02–0.16) had lower odds of having anemia. A moderate level of correlation of Hb level with the gestational age (R = 0.574, P value: <.001) was seen in the study. The prevalence of anemia is a serious public health problem among the women visiting ante natal checkup in Burtibang hospital. Later trimester of the pregnancy had higher risks of having anemia in comparison to the first and the gestational age of the women was a significant predictor of Hb level among the population.
- Open Access
- 18 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (5) , 2180-2185
Drug reaction with eosinophilia and systemic symptoms syndrome secondary to isoniazid and ethambutol: a case report and literature review
Introduction: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening condition precipitated by reaction of therapeutic drugs. The prevalence of potential antitubercular therapy (ATT)-induced DRESS is 1.2%. Case presentation: A 71-year-old female patient after 5 weeks of starting ATT complaints of fever, vomiting, dizziness, and generalized itchy maculopapular rash over the body. It was associated with marked eosinophilia (absolute eosinophil count 3094 cell/mm3, 36% in peripheral blood smear). Discussion: Fever, rash, lymphadenopathy, and internal organ involvement with marked eosinophilia constitute the major clinical manifestations of DRESS. RegiSCAR scoring system is usually used to diagnose DRESS. Identification of the culprit drug is based on the temporal correlation of symptoms with drug exposure and rechallenge test, patch test and lymphocytic transformation tests may be valuable adjunctive tools. Treatment includes withdrawal of offending agent and use of topical or systemic corticosteroids, antihistamines, cyclosporin or JAK inhibitor with clinical judgement. Conclusion: Clinicians from the tuberculosis burden region must be aware of DRESS associated with ATT and they must counsel the patient properly before prescription and manage them without delay if DRESS ensues.
- 18 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (5) , 2180-2185
Open AccessDrug reaction with eosinophilia and systemic symptoms syndrome secondary to isoniazid and ethambutol: a case report and literature review
Introduction: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening condition precipitated by reaction of therapeutic drugs. The prevalence of potential antitubercular therapy (ATT)-induced DRESS is 1.2%. Case presentation: A 71-year-old female patient after 5 weeks of starting ATT complaints of fever, vomiting, dizziness, and generalized itchy maculopapular rash over the body. It was associated with marked eosinophilia (absolute eosinophil count 3094 cell/mm3, 36% in peripheral blood smear). Discussion: Fever, rash, lymphadenopathy, and internal organ involvement with marked eosinophilia constitute the major clinical manifestations of DRESS. RegiSCAR scoring system is usually used to diagnose DRESS. Identification of the culprit drug is based on the temporal correlation of symptoms with drug exposure and rechallenge test, patch test and lymphocytic transformation tests may be valuable adjunctive tools. Treatment includes withdrawal of offending agent and use of topical or systemic corticosteroids, antihistamines, cyclosporin or JAK inhibitor with clinical judgement. Conclusion: Clinicians from the tuberculosis burden region must be aware of DRESS associated with ATT and they must counsel the patient properly before prescription and manage them without delay if DRESS ensues.
- Open Access
- 18 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies
Longitudinally extensive transverse myelitis (LETM) is characterized by contiguous immune-mediated inflammatory lesion of the spinal cord extending more than three vertebral segments. Neuromyelitis optica spectrum disorder (NMOSD) is the most common and important cause of LETM. This study aims to evaluate the demographic profile, clinical presentations, neuroimaging features, laboratory parameters, and etiologies of LETM and differentiates NMOSD from other etiologies of LETM. This retrospective cross-sectional study was conducted at the Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal. After receiving clearance from the ethical committee, a retrospective chart review was conducted and records of all the inpatient LETM cases admitted from March 2018 to June 2020 were obtained. From the patient records, the following information was extracted: the demographic profile, clinical presentations, neuroimaging features, cerebrospinal fluid analysis, serum anti-aquaporin-4 (AQP4) immunoglobulin G status, hemogram, infectious disease profile, inflammatory markers, and auto-immune panels. Descriptive analysis of data was performed with SPSS statistics 23.0 version (IBM Corp, Armonk, NY, USA). In our study, the mean age of LETM patients was 36.58 years, and 12 out of 19 (63.15%) patients were young, with an age less than 40 years. A total of 13 (68.40%) patients were male, with a male-to-female ratio of 2.16. Seven (36.80%) patients had a clinical diagnosis of NMOSD with anti-AQP4 antibody-positive status, four (21.10%) had unknown etiology, three (15.8%) had post-infectious transverse myelitis, and three (15.80%) had a diagnosis of idiopathic transverse myelitis. There was a single case (5.30%) of cervical spondylotic myelopathy and leukemic transverse myelitis each. The common presenting symptoms of LETM were bladder dysfunction, paraparesis, quadriparesis, and visual impairment. Visual involvement, either unilateral or bilateral, was common in NMOSD and LETM of unknown etiology category. Similarly, brain lesion was common in patients with NMOSD and LETM of unknown etiology category. LETM is a heterogeneous disorder with diverse etiologies and clinical presentations. NMOSD is an important cause of LETM that predominantly affects females. Optic neuritis can be seen in LETM of various etiologies, but it is more common in anti-AQP4-positive NMOSD patients. Brain lesions in LETM are common in anti-AQP4-positive NMOSD.
- 18 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Open AccessLongitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies
Longitudinally extensive transverse myelitis (LETM) is characterized by contiguous immune-mediated inflammatory lesion of the spinal cord extending more than three vertebral segments. Neuromyelitis optica spectrum disorder (NMOSD) is the most common and important cause of LETM. This study aims to evaluate the demographic profile, clinical presentations, neuroimaging features, laboratory parameters, and etiologies of LETM and differentiates NMOSD from other etiologies of LETM. This retrospective cross-sectional study was conducted at the Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal. After receiving clearance from the ethical committee, a retrospective chart review was conducted and records of all the inpatient LETM cases admitted from March 2018 to June 2020 were obtained. From the patient records, the following information was extracted: the demographic profile, clinical presentations, neuroimaging features, cerebrospinal fluid analysis, serum anti-aquaporin-4 (AQP4) immunoglobulin G status, hemogram, infectious disease profile, inflammatory markers, and auto-immune panels. Descriptive analysis of data was performed with SPSS statistics 23.0 version (IBM Corp, Armonk, NY, USA). In our study, the mean age of LETM patients was 36.58 years, and 12 out of 19 (63.15%) patients were young, with an age less than 40 years. A total of 13 (68.40%) patients were male, with a male-to-female ratio of 2.16. Seven (36.80%) patients had a clinical diagnosis of NMOSD with anti-AQP4 antibody-positive status, four (21.10%) had unknown etiology, three (15.8%) had post-infectious transverse myelitis, and three (15.80%) had a diagnosis of idiopathic transverse myelitis. There was a single case (5.30%) of cervical spondylotic myelopathy and leukemic transverse myelitis each. The common presenting symptoms of LETM were bladder dysfunction, paraparesis, quadriparesis, and visual impairment. Visual involvement, either unilateral or bilateral, was common in NMOSD and LETM of unknown etiology category. Similarly, brain lesion was common in patients with NMOSD and LETM of unknown etiology category. LETM is a heterogeneous disorder with diverse etiologies and clinical presentations. NMOSD is an important cause of LETM that predominantly affects females. Optic neuritis can be seen in LETM of various etiologies, but it is more common in anti-AQP4-positive NMOSD patients. Brain lesions in LETM are common in anti-AQP4-positive NMOSD.